Consideration of ketogenic metabolic therapy as a complementary or alternative approach for managing breast cancer

Basit Öğe Kaydı
dc.contributor.authorSeyfried, Thomas N.
dc.contributor.authorMukherjee, Purna
dc.contributor.authorİyikesici, Mehmet S.
dc.contributor.authorSlocum, Abdul
dc.contributor.authorKalamian, Miriam
dc.contributor.authorSpinosa, Jean-Pierre
dc.contributor.authorChinopoulos, Christos
dc.date.accessioned2021-05-15T12:42:25Z
dc.date.available2021-05-15T12:42:25Z
dc.date.issued2020
dc.departmentTıp Fakültesi, Onkoloji Anabilim Dalıen_US
dc.descriptionChinopoulos, Christos/0000-0003-0183-4149
dc.description.abstractBreast cancer remains as a significant cause of morbidity and mortality in women. Ultrastructural and biochemical evidence from breast biopsy tissue and cancer cells shows mitochondrial abnormalities that are incompatible with energy production through oxidative phosphorylation (OxPhos). Consequently, breast cancer, like most cancers, will become more reliant on substrate level phosphorylation (fermentation) than on oxidative phosphorylation (OxPhos) for growth consistent with the mitochondrial metabolic theory of cancer. Glucose and glutamine are the prime fermentable fuels that underlie therapy resistance and drive breast cancer growth through substrate level phosphorylation (SLP) in both the cytoplasm (Warburg effect) and the mitochondria (Q-effect), respectively. Emerging evidence indicates that ketogenicmetabolic therapy (KMT) can reduce glucose availability to tumor cells while simultaneously elevating ketone bodies, a non-fermentable metabolic fuel. It is suggested that KMT would be most effective when used together with glutamine targeting. Information is reviewed for suggesting how KMT could reduce systemic inflammation and target tumor cells without causing damage to normal cells. Implementation of KMT in the clinic could improve progression free and overall survival for patients with breast cancer.en_US
dc.description.sponsorshipFoundation for Metabolic Cancer Therapies; Claudia Peltz Foundation; George Yu Foundation; Kenneth Rainin Foundation; Boston College Research Expense Funden_US
dc.description.sponsorshipWe thank the Foundation for Metabolic Cancer Therapies, CrossFit Inc., the Nelson and Claudia Peltz Foundation, Joseph C. Maroon, the George Yu Foundation, Kenneth Rainin Foundation, and the Boston College Research Expense Fund for their support.en_US
dc.identifier.doi10.3389/fnut.2020.00021
dc.identifier.issn2296-861X
dc.identifier.pmid32219096
dc.identifier.scopus2-s2.0-85082725502
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3389/fnut.2020.00021
dc.identifier.urihttps://hdl.handle.net/20.500.12939/936
dc.identifier.volume7en_US
dc.identifier.wosWOS:000525526600001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorİyikesici, Mehmet S.
dc.language.isoen
dc.publisherFrontiers Media Saen_US
dc.relation.ispartofFrontiers in Nutrition
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGlycolysisen_US
dc.subjectSurvivalen_US
dc.subjectGlutaminolysisen_US
dc.subjectNon-Toxicen_US
dc.subjectFermentationen_US
dc.subjectMetastasisen_US
dc.subjectInflammationen_US
dc.titleConsideration of ketogenic metabolic therapy as a complementary or alternative approach for managing breast cancer
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Consideration of Ketogenic Metabolic Therapy as a Complementary or Alternative Approach for Managing Breast Cancer.pdf
Boyut:
863.37 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/ Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu